Express News | PCT Therapeutics Shares Are Trading Lower. The Company Announced Interim Results From the Phase 2 PIVOT-HD Study of PTC518 in Huntington's Disease Patients

BenzingaJun 20 10:34 ET

PTC Therapeutics Says FDA Lifts Clinical Hold On Investigational Study In Patients With Rare Weak Nerve Cell Disorder

Thursday, PTC Therapeutics Inc (NASDAQ:PTCT) shared interim results from the Phase 2 PIVOT-HD study of PTC518 in Huntington's disease (HD) patients.HD is an inherited condition in which nerve cells in

BenzingaJun 20 10:09 ET

Sector Update: Health Care Stocks Lean Lower Pre-Bell Thursday

Health care stocks were lower pre-bell Thursday as the Health Care Select Sector SPDR Fund (XLV) was down 0.3% and iShares Biotechnology ETF (IBB) was recently declining by 0.3%. Jazz Pharmaceuticals

MT NewswiresJun 20 09:14 ET

PTC Therapeutics Reports Favorable Interim Results in Huntington's Disease Study; US FDA Lifts Clinical Hold

PTC Therapeutics (PTCT) said Thursday that the US Food and Drug Administration has lifted the partial clinical hold on its PTC518 program following favorable interim results from the phase 2 PIVOT-HD

MT NewswiresJun 20 08:53 ET

Express News | Royalty Pharma: PTC Therapeutics Exercised Option to Sell Half of Retained Royalties on Roche's Evrysdi to Co's Unit for About $242 Mln Upfront

ReutersJun 20 08:16 ET

Express News | PTC Therapeutics Shared Interim Results From Phase 2 PIVOT-HD Study Of PTC518 In Huntington's Disease, Showing Dose-dependent Lowering Of Mutant Huntingtin Protein In Blood/Cerebrospinal Fluid And Favorable Trends On Several Relevant Clinical Assessments

BenzingaJun 20 06:34 ET